Amphastar Pharmaceuticals
AMPH | NASDAQ
$29.17
-$0.20 (-0.68%)
At close: Nov 16, 2026, 4:00 PM ET
$29.17
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Amphastar Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
Key Executives
| Name | Position |
|---|---|
| Yongfeng Zhang | Co-Founder, President, Chief Executive Officer, Chief Scientific Officer & Director |
| William J. Peters | Chief Financial Officer, Executive Vice President of Finance, Treasurer & Director |
| Ziping Luo | Chairman of the Board, Chief Scientist & Chief Operating Officer |
| Dan Dischner | Senior Vice President of Human Resources & Corporate Communication |
| Jacob Liawatidewi | Executive Vice President of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director |
| Rong Zhou | Senior EVice President of Production & EVP of Scientific Affairs |
| Tony Marrs | Executive Vice President of Regulatory Affairs & Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 23, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 03, 2026 | 4 | Filing |
| Aug 12, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 13, 2026 | 4 | Filing |
| Jul 13, 2026 | 3 | Filing |
Amphastar Pharmaceuticals
| Country | United States |
| IPO Date | Jun 25, 2014 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 1,976 |
| CEO | Yongfeng Zhang |
Contact Details
11570 6th Street Rancho Cucamonga,
California 91730 United States
Stock Details
| Ticker Symbol | AMPH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001297184 |
| CUSIP Number | 03209R103 |
| ISIN Number | US03209R1032 |
| SIC Code | 2834 |
Recent News
- 10 days ago / seekingalpha.comAmphastar Pharmaceuticals, Inc. (AMPH) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comAmphastar (AMPH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- 11 days ago / marketbeat.comAmphastar Pharmaceuticals Q3 Earnings Call Highlights
- 11 days ago / zacks.comAmphastar Pharmaceuticals (AMPH) Tops Q3 Earnings and Revenue Estimates
- 11 days ago / prnewswire.comAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026
- 19 days ago / zacks.comAnalysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
- 19 days ago / prnewswire.comAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026
- 1 month ago / zacks.comShould Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
- 6 months ago / seekingalpha.comAmphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
- 6 months ago / zacks.comCompared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics
Add to Watchlist
Select watchlists to add or remove AMPH